The restricted sample size reflected the inadequate knowledge of genomics in Chinese population with MM, and clinical trials [44, 45] targeting BAP1 have shown promising results suggesting the urgency of expanded sample size for further studies. The gene discussed is BAP1; the disease is Miyoshi myopathy.